Clinical Trials in New York State

Showing 1461-1480 of 8,190 trials

Access Cannulation Trial II

NCT05490225

This is a pivotal, interventional, prospective, single-arm, open-label, multi-site clinical investigation intended to support FDA clearance of the study device based on the safety and efficacy of the device in cannulating arteriovenous fistulas (AVFs) for hemodialysis procedures.

Dialysis; ComplicationsVascular Access Complication

Voyager Biomedical100 participantsStarted Apr 2025

Dothan, Alabama, United States • Riverside, California, United States • Boston, Massachusetts, United States +5 more locations

Active Not RecruitingPhase 1/269 miles

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

NCT03172754

This is a Phase I/II, open-label, multi-center study of axitinib in combination with nivolumab in patients with previously treated and untreated advanced RCC. This clinical study will be composed of a dose finding phase (Phase I) and two parallel dose expansion phases (Phase II). The dose finding phase will assess the safety of the combination and establish a recommended phase II dose (RP2D, the highest tested dose that is declared safe and tolerable by the Investigators and the Sponsor Investigator) in patients with advanced RCC who have received prior systemic therapy for metastatic disease. Phase II will evaluate the efficacy of the combination at the RP2D in two parallel expansion cohorts in both previously treated and treatment naïve patients.

Renal Cell Carcinoma

Fox Chase Cancer Center98 participantsStarted Jun 2017

Baltimore, Maryland, United States • Albany, New York, United States • New York, New York, United States +1 more locations

Access Cannulation Trial II

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Find Trials by Condition in New York State

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

OCS Heart Perfusion Post-Approval Registry

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)

Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Individualizing Treatment for Asthma in Primary Care (Full Study)

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

A Study of XMT-1660 in Participants With Solid Tumors

Clinical Validation Study of the Eximis CS (Contained Segmentation) System

Metabolomics of Obstructive Sleep Apnea

Using Re-inforcement Learning to Automatically Adapt a Remote Therapy Intervention (RTI) for Reducing Adolescent Violence Involvement

The CALERIE™ Legacy Study

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)